SBC Medical Appoints Sheng-FU Hsiao as Chief Technology Officer to Accelerate AI-Driven Transformation
SBC Medical Group Holdings Incorporated (“SBC Medical” or the “Company”), a global provider of comprehensive management and consulting services for medical institutions and clinic networks, has announced the appointment of Sheng-FU Hsiao as Chief Technology Officer (CTO), effective March 1, 2026. This strategic leadership appointment marks a significant milestone in the Company’s long-term innovation roadmap and reflects its firm commitment to technological transformation across the healthcare management ecosystem.
The appointment aligns closely with SBC Medical’s 2026 corporate strategy titled “Sophisticating the Management Framework through AI and DX (Digital Transformation).” Through this initiative, the Company seeks to fundamentally redesign its operational and management systems by embedding artificial intelligence at the core of its infrastructure.
Transforming the Medical Management Model
The global healthcare industry faces mounting structural challenges, including workforce shortages, rising operational costs, inconsistent quality control, and growing demands for transparency and efficiency. Historically, many medical management models have relied heavily on labor-intensive, manual processes that limit scalability and operational agility.
Recognizing these challenges, SBC Medical is transitioning from a traditional operational framework to an AI-driven management infrastructure. The Company aims to establish what it calls an “Automated Management Infrastructure”—a next-generation operating system designed to optimize every layer of medical management, from strategic decision-making to real-time operational execution.
This system is being developed to deliver high reproducibility, scalability, and efficiency across all clinic locations globally. By embedding automation, predictive analytics, and intelligent workflows, SBC Medical intends to create a management ecosystem capable of adapting dynamically to patient demand, regulatory requirements, and market expansion.
Leadership to Drive AI Innovation
To lead this ambitious transformation, SBC Medical welcomed Sheng-FU Hsiao, a seasoned technology executive with deep expertise in artificial intelligence implementation, IT governance, and enterprise-scale system modernization.
Mr. Hsiao brings a strong track record of successfully leading AI-focused organizations and building robust technology infrastructures, particularly in pre-IPO corporate environments. His experience spans automation of complex operations, modernization of legacy systems, and the integration of scalable digital architectures.
In his previous roles, Mr. Hsiao spearheaded the implementation of AI-powered call center systems that significantly enhanced operational efficiency. These systems reduced workforce requirements by approximately 31%—equivalent to nearly 50 employees—while simultaneously improving customer response times by 30%. His work demonstrated how AI integration can simultaneously lower costs and elevate service standards.
Additionally, Mr. Hsiao successfully transformed outdated, 20-year-old legacy IT systems into flexible microservices-based architectures. This modernization allowed organizations to accelerate software development cycles, deploy new features more rapidly, and adapt systems to evolving business needs with minimal disruption.
At SBC Medical, Mr. Hsiao will oversee the comprehensive modernization of core systems operating across 283 global clinic units. He will also lead the strategic transformation of the Group’s extensive clinical, operational, and customer data into a powerful AI-driven asset. A key focus of his mandate will be ensuring the highest standards of cybersecurity, ethical AI governance, and data privacy compliance.
Key Initiatives for AI Transformation
Mr. Hsiao will collaborate closely with Vice President Yuya Yoshida to execute the Company’s AI strategy. Mr. Yoshida leads the internal innovation division known as the “SBC AI Lab,” which focuses on research and development of AI technologies tailored to medical management. By combining Mr. Yoshida’s strategic vision with Mr. Hsiao’s execution expertise, SBC Medical aims to redefine its operational “management operating system.”
The Company’s AI transformation strategy is structured around three primary pillars:
1. Autonomous Operations and Advanced Management
A central objective is the implementation of AI-powered infrastructure capable of optimizing all administrative and operational processes. This includes patient scheduling, workflow coordination, inventory control, financial management, and resource allocation.
AI-Powered Call Centers:
The Company plans to deploy 24/7/365 AI-enabled call center systems to manage patient inquiries and appointment scheduling. These systems will significantly reduce query response times by approximately 30%, while ensuring uninterrupted availability across global time zones.
Core System Modernization:
SBC Medical will modernize its existing core systems operating in 283 global clinic units (as of December 2025, including SBC, Rize Clinic, Gorilla Clinic, AHH, JUN CLINIC, and OrangeTwist brand clinics). Transitioning to a microservices-based architecture will shorten implementation timelines for new features and system upgrades, enabling faster innovation cycles.
Administrative Automation Expansion:
AI-driven automation will be extended to back-office functions to reduce manual labor hours and minimize inventory loss. Intelligent inventory tracking systems will help prevent waste and improve procurement accuracy.
Strengthening Internal Development:
By expanding in-house development capabilities, SBC Medical aims to maximize return on investment (ROI) while reducing reliance on external vendors. This approach ensures better alignment between technology development and strategic business objectives.
Leveraging 6.63 Million Annual Consultations:
The Company manages data from approximately 6.63 million annual medical consultations (as of December 2025, excluding free consultations). By analyzing this vast dataset, AI systems will optimize physician allocation, forecast patient demand, and improve consultation-to-treatment conversion rates.
2. Innovation in Customer Experience (UX)
SBC Medical is committed not only to operational efficiency but also to enhancing patient engagement and transparency.
AI Concierge:
An AI-powered virtual concierge will provide patients with continuous 24-hour support. This system will guide patients through appointment booking, pre-treatment preparation, post-treatment follow-ups, and frequently asked questions, ensuring seamless communication.
AI Mirrors:
To improve transparency in treatment outcomes, SBC Medical plans to introduce “AI Mirrors.” These tools will use objective data visualization technologies to demonstrate potential and actual treatment results, enhancing patient trust and informed decision-making.
By integrating AI into customer-facing services, SBC Medical aims to create a highly personalized and data-driven patient journey that strengthens satisfaction and long-term loyalty.
3. Global Expansion of the AI Medical Operating System
SBC Medical has already validated its AI-driven management framework in Japan. The next phase involves exporting this proven operating model to international markets, including the United States and Southeast Asia.
The Company’s goal is to rapidly replicate high-quality clinical operations across borders by deploying its native AI management platform globally. This standardized yet flexible system will allow new clinics to adopt best practices immediately, reducing ramp-up time and ensuring consistent service quality worldwide.
About Sheng-FU Hsiao
Sheng-FU Hsiao is an internationally experienced technology executive with a multidisciplinary background. After graduating from National United University in Taiwan, he pursued further studies at Curtin University in Australia. He began his professional career in business management roles in China before relocating to Japan in 2008.
Over the past eight years, Mr. Hsiao has served as CTO in multiple organizations, leading restructuring initiatives and advanced technology development programs that drove measurable growth. Most recently, he held dual roles as CEO and CTO at an AI-specialized company, where he oversaw both strategic leadership and technological execution.
Mr. Hsiao is fluent in Japanese, English, Mandarin, and Taiwanese, enabling him to operate effectively in multinational business environments and support SBC Medical’s global expansion efforts.
Vision for the Future
Commenting on his appointment, Mr. Hsiao stated:
I am confident that the implementation of the ‘Automated Management Infrastructure’ envisioned by SBC Medical will bring about a paradigm shift in the medical sector. By leveraging advanced AI technologies and transforming our vast data assets into strategic value, we can deliver the highest standard of medical experience to clients worldwide. At the same time, we will create an environment where healthcare professionals can focus on highly specialized tasks that truly require human expertise.”
Under his leadership, SBC Medical aims to redefine how medical institutions are managed in the digital age—balancing automation with ethical governance, efficiency with transparency, and scalability with quality.
About SBC Medical Group Holdings Incorporated:
SBC Medical Group Holdings Incorporated is a comprehensive medical group operating a wide variety of franchised businesses across diverse fields of medicine, including advanced aesthetic medicine, dermatology, orthopedics, fertility treatments, dentistry, AGA (hair restoration), and ophthalmology. The company manages a diversified portfolio of clinic brands and is actively expanding its global footprint, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the company was listed on Nasdaq and, in June 2025, was selected for inclusion in the Russell 3000® Index, a broad benchmark index of the United States equity market. Guided by its Group Purpose — “To contribute to the well-being of people around the world through medical innovation” — SBC Medical Group Holdings Incorporated continues to offer safe, reliable, and high-quality medical services while further strengthening its international reputation for quality and trust in healthcare.
This press release contains forward-looking statements. Forward-looking statements are not historical facts or statements about current conditions, but represent only the Company’s beliefs regarding future events and performance, many of which, by their nature, are inherently uncertain and outside the Company’s control. These forward-looking statements reflect the Company’s current views regarding, among other things, the Company’s product launch plans and strategies; revenue and profit growth; and business prospects. In some cases, forward-looking statements can be identified by the use of words such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projects,” “predicts,” “potential,” “aims,” or “expects,” or the negative of these or similar terms. The Company cautions readers not to place undue reliance on any forward-looking statements, which are valid only as of the date of this release and are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Forward-looking statements are based on management’s current expectations and are not guarantees of future performance. The Company undertakes no obligation to publicly disclose any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in the events, conditions, or circumstances on which such statements are based, except as required by law. Factors that could cause actual results to differ materially from current expectations may arise from time to time, and it is not possible for the Company to foresee them all. These factors include, among others, changes in global, regional, or local economic, business, competitive, market, and regulatory conditions, and those listed under the heading “Risk Factors” and elsewhere in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), which can be accessed on the SEC’s
